PSMA I&T combines a high-affinity peptide motif with a chelator system tuned for imaging-ligand research. Residue placement supports receptor engagement and structural stability. Researchers examine its metal-binding behavior and solution conformation. Applications include receptor-mapping studies, ligand optimization, and chelator-peptide integration.
CAT No: R2559
CAS No:2192281-54-0
Synonyms/Alias:PSMA I&T;2192281-54-0;PSMA-I&T?;SCHEMBL22011359;EX-A5972;DA-57198;MS-32188;HY-148761;CS-0638882;(2S)-2-[[(1S)-1-carboxy-5-[[8-[[(5R)-5-carboxy-5-[[(2R)-2-[[(2R)-2-[[4-carboxy-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]butanoyl]amino]-3-(4-hydroxy-3-iodophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]pentyl]amino]-8-oxooctanoyl]amino]pentyl]carbamoylamino]pentanedioic acid;
Psma I&T, also known as Prostate-Specific Membrane Antigen Inhibitor & Theranostic, is a sophisticated carbohydrate-based compound designed to selectively target the prostate-specific membrane antigen (PSMA) expressed on the surface of certain cancer cells. Its unique structure enables high-affinity binding to PSMA, facilitating both diagnostic imaging and therapeutic applications in preclinical research settings. As a versatile molecular tool, Psma I&T integrates advanced targeting capabilities with the flexibility for conjugation to various imaging agents or payloads, making it an invaluable asset in the development and validation of novel cancer research strategies. The compound's molecular architecture supports efficient cellular uptake and retention, which enhances the sensitivity and specificity of subsequent analyses. Researchers value Psma I&T for its stability, ease of modification, and proven performance in a range of experimental models, where precise localization and quantification of PSMA expression are critical. In addition, the availability of this compound has accelerated progress in the field of targeted molecular imaging and therapy, offering a powerful platform for preclinical investigations into cancer biology and treatment response.
Molecular Imaging: In the realm of molecular imaging, Psma I&T is extensively utilized as a targeting ligand for the development of radiolabeled probes, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) studies. By conjugating the compound to radioisotopes such as gallium-68 or lutetium-177, researchers can achieve highly specific visualization of PSMA-expressing tumors in animal models. This application enables the non-invasive assessment of tumor burden, metastasis, and heterogeneity, thereby supporting the optimization of imaging protocols and the evaluation of new diagnostic agents. The ability of Psma I&T to provide clear, high-contrast images greatly facilitates the early detection and monitoring of disease progression in preclinical cancer research.
Targeted Drug Delivery: Another prominent application involves the use of Psma I&T as a targeting moiety for the delivery of therapeutic agents directly to PSMA-positive cells. By linking cytotoxic drugs, nanoparticles, or other therapeutic payloads to the compound, researchers can enhance the selectivity and efficacy of experimental treatment regimens while minimizing off-target effects. This targeted delivery approach is instrumental in investigating the mechanisms of drug uptake, biodistribution, and therapeutic response in vivo. The specificity afforded by Psma I&T supports the development of more effective and safer therapeutic strategies for prostate cancer and other PSMA-expressing malignancies in laboratory models.
Theranostic Agent Development: Psma I&T serves as a foundational scaffold for the creation of theranostic agents, which combine diagnostic and therapeutic functions within a single molecular entity. By enabling the simultaneous imaging and treatment of PSMA-positive tumors, these agents offer a powerful means of evaluating the real-time efficacy of novel therapies in preclinical studies. The dual functionality of Psma I&T-based constructs allows researchers to correlate imaging signals with therapeutic outcomes, providing valuable insights into tumor biology, drug resistance, and treatment optimization. This integrated approach is paving the way for more personalized and adaptive cancer research methodologies.
Biomarker Validation: In the context of biomarker validation, Psma I&T is employed to confirm the expression and functional relevance of PSMA in various cancer models. By selectively binding to PSMA, the compound facilitates the identification and quantification of this antigen in tissue samples, cell lines, and animal models. This capability is essential for validating PSMA as a target for experimental imaging and therapeutic interventions, as well as for understanding its role in tumor progression and metastasis. The use of Psma I&T in biomarker studies contributes to the refinement of preclinical models and the advancement of targeted cancer research.
Combination Therapy Research: The versatility of Psma I&T extends to its application in combination therapy research, where it is used to investigate the synergistic effects of targeted agents with other treatment modalities. By incorporating the compound into experimental protocols alongside chemotherapy, immunotherapy, or radiotherapy, scientists can evaluate the potential for enhanced therapeutic outcomes and reduced toxicity. The precise targeting offered by Psma I&T enables the design of combination strategies that maximize tumor cell kill while sparing healthy tissues, thereby informing the development of next-generation multi-modal cancer therapies in preclinical settings. Overall, the diverse applications of Psma I&T underscore its value as a critical tool for advancing the understanding and treatment of PSMA-expressing cancers in the research laboratory.
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
3. Implications of ligand-receptor binding kinetics on GLP-1R signalling
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More